Search Results - "DeMarini, Douglas J."

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor by KIM, Kevin B, KEFFORD, Richard, GONZALEZ, Rene, OTT, Patrick A, LONG, Georgina V, GARDNER, Olivia S, OUELLET, Daniele, YANMEI XU, DEMARINI, Douglas J, LE, Ngocdiep T, PATEL, Kiran, LEWIS, Karl D, PAVLICK, Anna C, INFANTE, Jeffrey R, RIBAS, Antoni, SOSMAN, Jeffrey A, FECHER, Leslie A, MILLWARD, Michael, MCARTHUR, GrantA, HWU, Patrick

“…BRAF mutations promote melanoma cell proliferation and survival primarily through activation of MEK. The purpose of this study was to determine the response…”
Get full text

Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies by Forero-Torres, Andres, Ramchandren, Radhakrishnan, Yacoub, Abdulraheem, Wertheim, Michael S., Edenfield, William J., Caimi, Paolo, Gutierrez, Martin, Akard, Luke, Escobar, Carolina, Call, Justin, Persky, Daniel, Iyer, Swaminathan, DeMarini, Douglas J., Zhou, Li, Chen, Xuejun, Dawkins, Fitzroy, Phillips, Tycel J.

“…This phase 1/2 study assessed parsaclisib (INCB050465), a next-generation, potent, and highly selective phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor, in…”
Get full text

A Septin-Based Hierarchy of Proteins Required for Localized Deposition of Chitin in the Saccharomyces cerevisiae Cell Wall by DeMarini, Douglas J., Alison E. M. Adams, Fares, Hanna, De Virgilio, Claudio, Valle, Giorgio, Chuang, John S., Pringle, John R.

“…Just before bud emergence, a Saccharomyces cerevisiae cell forms a ring of chitin in its cell wall; this ring remains at the base of the bud as the bud grows…”
Get full text

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial by Falchook, Gerald S, Dr, Lewis, Karl D, MD, Infante, Jeffrey R, MD, Gordon, Michael S, MD, Vogelzang, Nicholas J, MD, DeMarini, Douglas J, PhD, Sun, Peng, PhD, Moy, Christopher, MS, Szabo, Stephen A, BA, Roadcap, Lori T, MS, Peddareddigari, Vijay GR, MD, Lebowitz, Peter F, MD, Le, Ngocdiep T, MD, Burris, Howard A, MD, Messersmith, Wells A, MD, O'Dwyer, Peter J, Prof, Kim, Kevin B, MD, Flaherty, Keith, MD, Bendell, Johanna C, MD, Gonzalez, Rene, Prof, Kurzrock, Razelle, Prof, Fecher, Leslie A, MD

“…Summary Background MEK is a member of the MAPK signalling cascade that is commonly activated in melanoma. Direct inhibition of MEK blocks cell proliferation…”
Get full text

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial by Infante, Jeffrey R, Dr, Fecher, Leslie A, MD, Falchook, Gerald S, MD, Nallapareddy, Sujatha, MD, Gordon, Michael S, MD, Becerra, Carlos, MD, DeMarini, Douglas J, PhD, Cox, Donna S, PhD, Xu, Yanmei, MS, Morris, Shannon R, MD, Peddareddigari, Vijay GR, MD, Le, Ngocdiep T, MD, Hart, Lowell, MD, Bendell, Johanna C, MD, Eckhardt, Gail, MD, Kurzrock, Razelle, Prof, Flaherty, Keith, MD, Burris, Howard A, MD, Messersmith, Wells A, MD

“…Summary Background Inhibition of MEK stops cell proliferation and induces apoptosis; therefore, this enzyme is a key anticancer target. Trametinib is a…”
Get full text

Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma by Ouellet, Daniele, Kassir, Nastya, Chiu, Joannellyn, Mouksassi, Mohamad-Samer, Leonowens, Cathrine, Cox, Donna, DeMarini, Douglas J., Gardner, Olivia, Crist, Wendy, Patel, Kiran

“…Purpose To characterize the pharmacokinetics of oral trametinib, a first in class MEK inhibitor, identify covariates, and describe the relationship between…”
Get full text

Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202) by Coleman, Morton, Belada, David, Casasnovas, René-Olivier, Gressin, Rémy, Lee, Hui-Peng, Mehta, Amitkumar, Munoz, Javier, Verhoef, Gregor, Corrado, Claudia, DeMarini, Douglas J., Zhao, Wanying, Li, Jia, Fay, Keith

“…Parsaclisib, a potent, highly selective, next-generation PI3Kδ inhibitor, was evaluated as monotherapy in CITADEL-202 (NCT02998476), an open-label,…”
Get full text

Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma by Schadendorf, Dirk, Amonkar, Mayur M, Stroyakovskiy, Daniil, Levchenko, Evgeny, Gogas, Helen, de Braud, Filippo, Grob, Jean-Jacques, Bondarenko, Igor, Garbe, Claus, Lebbe, Celeste, Larkin, James, Chiarion-Sileni, Vanna, Millward, Michael, Arance, Ana, Mandalà, Mario, Flaherty, Keith T, Nathan, Paul, Ribas, Antoni, Robert, Caroline, Casey, Michelle, DeMarini, Douglas J, Irani, Jhangir G, Aktan, Gursel, Long, Georgina V

“…Abstract Aim To present the impact of treatments on health-related quality of life (HRQoL) from the double-blind, randomised phase III COMBI-d study that…”
Get full text

Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in Melanoma by Villanueva, Jessie, Infante, Jeffrey R., Krepler, Clemens, Reyes-Uribe, Patricia, Samanta, Minu, Chen, Hsin-Yi, Li, Bin, Swoboda, Rolf K., Wilson, Melissa, Vultur, Adina, Fukunaba-Kalabis, Mizuho, Wubbenhorst, Bradley, Chen, Thomas Y., Liu, Qin, Sproesser, Katrin, DeMarini, Douglas J., Gilmer, Tona M., Martin, Anne-Marie, Marmorstein, Ronen, Schultz, David C., Speicher, David W., Karakousis, Giorgos C., Xu, Wei, Amaravadi, Ravi K., Xu, Xiaowei, Schuchter, Lynn M., Herlyn, Meenhard, Nathanson, Katherine L.

“…Although BRAF and MEK inhibitors have proven clinical benefits in melanoma, most patients develop resistance. We report a de novo MEK2-Q60P mutation and BRAF…”
Get full text

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study by Zinzani, Pier Luigi, Trněný, Marek, Ribrag, Vincent, Zilioli, Vittorio Ruggero, Walewski, Jan, Christensen, Jacob Haaber, Delwail, Vincent, Rodriguez, Guillermo, Venugopal, Parameswaran, Coleman, Morton, Dartigeas, Caroline, Patti, Caterina, Pane, Fabrizio, Jurczak, Wojciech, Taszner, Michal, Paneesha, Shankara, Zheng, Fred, DeMarini, Douglas J., Jiang, Wei, Gilmartin, Aidan, Mehta, Amitkumar

“…Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies. In…”
Get full text

Trametinib for patients with advanced melanoma – Authors' reply by Falchook, Gerald S, Moy, Christopher, DeMarini, Douglas J

Get full text

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study by Trněný, Marek, Avigdor, Abraham, McKinney, Matthew S., Paneesha, Shankara, Wahlin, Björn E., Hrom, John S., Cunningham, David, Morley, Nicholas, Canales, Miguel, Bastos-Oreiro, Mariana, Belada, David, Devizzi, Liliana, Zheng, Fred, DeMarini, Douglas J., Jiang, Wei, Jiang, Ping, Lynch, Ryan C.

“…Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This…”
Get full text

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034) by Prince, H. Miles, Hönemann, Dirk, Spencer, Andrew, Rizzieri, David A., Stadtmauer, Edward A., Roberts, Andrew W., Bahlis, Nizar, Tricot, Guido, Bell, Bill, DeMarini, Douglas J., Benjamin Suttle, A., Baker, Katherine L., Pandite, Lini N.

Get full text

Additional modules for versatile and economical PCR‐based gene deletion and modification in Saccharomyces cerevisiae by Longtine, Mark S., Mckenzie III, Amos, Demarini, Douglas J., Shah, Nirav G., Wach, Achim, Brachat, Arndt, Philippsen, Peter, Pringle, John R.

“…An important recent advance in the functional analysis of Saccharomyces cerevisiae genes is the development of the one‐step PCR‐mediated technique for deletion…”
Get full text

N-((1S)-1-{[4-((2S)-2-{[(2,4-dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide (GSK1016790A), a novel and potent transient receptor potential vanilloid 4 channel agonist induces urinary bladder contraction and hyperactivity: Part I by Thorneloe, Kevin S, Sulpizio, Anthony C, Lin, Zuojun, Figueroa, David J, Clouse, Angela K, McCafferty, Gerald P, Chendrimada, Tim P, Lashinger, Erin S R, Gordon, Earl, Evans, Louise, Misajet, Blake A, Demarini, Douglas J, Nation, Josephine H, Casillas, Linda N, Marquis, Robert W, Votta, Bartholomew J, Sheardown, Steven A, Xu, Xiaoping, Brooks, David P, Laping, Nicholas J, Westfall, Timothy D

“…The transient receptor potential (TRP) vanilloid 4 (TRPV4) member of the TRP superfamily has recently been implicated in numerous physiological processes. In…”
Get more information

The septins: roles in cytokinesis and other processes by Longtine, Mark S, DeMarini, Douglas J, Valencik, Maria L, Al-Awar, Omayma S, Fares, Hanna, De Virgilio, Claudio, Pringle, John R

“…The septins are a novel family of proteins that were first recognized in yeast as proteins associated with the neck filaments. Recent work has shown that…”
Get full text

A Bni4-Glc7 phosphatase complex that recruits chitin synthase to the site of bud emergence by Kozubowski, Lukasz, Panek, Heather, Rosenthal, Ashley, Bloecher, Andrew, DeMarini, Douglas J, Tatchell, Kelly

“…Bni4 is a scaffold protein in the yeast Saccharomyces cerevisiae that tethers chitin synthase III to the bud neck by interacting with septin neck filaments and…”
Get full text

SPR28, a sixth member of the septin gene family in Saccharomyces cerevisiae that is expressed specifically in sporulating cells by De Virgilio, C, DeMarini, D.J, Pringle, J.R

“…The septins are a recently recognized family of proteins that are present in a wide variety of fungal and animal cells, where they are involved in cytokinesis…”
Get full text

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial by Long, Georgina V, MD, Stroyakovskiy, Daniil, MD, Gogas, Helen, MD, Levchenko, Evgeny, MD, de Braud, Filippo, MD, Larkin, James, FRCP, Garbe, Claus, Prof, Jouary, Thomas, MD, Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Chiarion-Sileni, Vanna, MD, Lebbe, Celeste, Prof, Mandalà, Mario, MD, Millward, Michael, Prof, Arance, Ana, MD, Bondarenko, Igor, Prof, Haanen, John B A G, Prof, Hansson, Johan, Prof, Utikal, Jochen, Prof, Ferraresi, Virginia, MD, Kovalenko, Nadezhda, Prof, Mohr, Peter, MD, Probachai, Volodymr, MD, Schadendorf, Dirk, Prof, Nathan, Paul, MD, Robert, Caroline, MD, Ribas, Antoni, Prof, DeMarini, Douglas J, PhD, Irani, Jhangir G, MA, Swann, Suzanne, PhD, Legos, Jeffrey J, PhD, Jin, Fan, MD, Mookerjee, Bijoyesh, MD, Flaherty, Keith, MD

“…Summary Background Previously, a study of ours showed that the combination of dabrafenib and trametinib improves progression-free survival compared with…”
Get full text

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma by Long, Georgina V, Stroyakovskiy, Daniil, Gogas, Helen, Levchenko, Evgeny, de Braud, Filippo, Larkin, James, Garbe, Claus, Jouary, Thomas, Hauschild, Axel, Grob, Jean Jacques, Chiarion Sileni, Vanna, Lebbe, Celeste, Mandalà, Mario, Millward, Michael, Arance, Ana, Bondarenko, Igor, Haanen, John B.A.G, Hansson, Johan, Utikal, Jochen, Ferraresi, Virginia, Kovalenko, Nadezhda, Mohr, Peter, Probachai, Volodymyr, Schadendorf, Dirk, Nathan, Paul, Robert, Caroline, Ribas, Antoni, DeMarini, Douglas J, Irani, Jhangir G, Casey, Michelle, Ouellet, Daniele, Martin, Anne-Marie, Le, Ngocdiep, Patel, Kiran, Flaherty, Keith

“…The addition of a MEK inhibitor to a BRAF inhibitor improved response rates by nearly 16 percentage points (from 51% to 67%) and improved progression-free…”
Get full text